El trial despide con honores a Adam Raga, el eterno antagonista de Toni Bou | Deportes – Go Health Pro

El trial despide con honores a Adam Raga, el eterno antagonista de Toni Bou | Deportes – Go Health Pro

A Adam Raga Sans (Ulldecona, Tarragona; 42 años) se le hará extraño dejar de una vez por todas la competición. Aunque es una decisión meditada desde el pasado verano, la intención de despedirse en casa, ante el público de la 48º edición del Trial Indoor de Barcelona, le ha obligado a mantenerse en plena forma … Read more

Zacks Small Cap Research – AEMD Treats First Patient in Australian Safety, Feasibility & Dose-Finding Clinical Trial of Hemopurifier – Go Health Pro

Zacks Small Cap Research – AEMD Treats First Patient in Australian Safety, Feasibility & Dose-Finding Clinical Trial of Hemopurifier – Go Health Pro

By M. Marin NASDAQ:AEMD Aethlon Medical (NASDAQ:AEMD) announced that the first patient in its Australian safety, feasibility and dose-finding clinical trial has been treated with the Hemopurifier. The trial is designed for patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment. In other words, the trial is evaluating the Hemopurifier … Read more

Zacks Small Cap Research – MTVA: Compelling Data for DA-1241 in Phase 2a MASH Trial… – Go Health Pro

Zacks Small Cap Research – MTVA: Compelling Data for DA-1241 in Phase 2a MASH Trial… – Go Health Pro

By David Bautz, PhD NASDAQ:MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Compelling Results for DA-1241 in Phase 2a MASH Trial On December 18, 2024, MetaVia Inc. (NASDAQ:MTVA) announced positive topline results from the 16-week Phase 2a clinical trial of DA-1241 in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH). The trial had two parts: … Read more

Zacks Small Cap Research – SNGX: Phase 3 FLASH2 Trial of HyBryte in CTCL Underway… – Go Health Pro

Zacks Small Cap Research – SNGX: Phase 3 FLASH2 Trial of HyBryte in CTCL Underway… – Go Health Pro

By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Phase 3 FLASH2 Trial of HyBryte in CTCL is Underway On December 16, 2024, Soligenix, Inc. (NASDAQ:SNGX) announced that patient enrollment has opened up for the confirmatory Phase 3 FLASH2 (Fluorescent Light Activated Synthetic Hypericin 2) trial of HyBryte in patients with … Read more

Zacks Small Cap Research – MNOV: Encouraging Interim Analysis for Phase 2b/3 ALS Trial… – Go Health Pro

By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Business Update Encouraging Interim Results from Phase 2b/3 COMBAT-ALS Trial On December 5, 2024, MediciNova, Inc. (NASDAQ:MNOV) announced a poster presentation at the 35th International Symposium on ALS/MND would feature a study update and interim analysis results from the ongoing Phase 2b/3 COMBAT-ALS trial … Read more